The Cancer Diaspora: A Rare Case of Pseudomyxoma Peritonei of Appendiceal Origin

Pseudomyxoma peritonei (PMP) is a rare clinical entity characterized by widespread mucinous implants in the peritoneal cavity. Commonly seen in females in their 50s, PMP typically originates from ruptured appendiceal mucoceles that find refuge in the peritoneal space. Rarely, PMP may originate from...

Full description

Saved in:
Bibliographic Details
Published in:JIM - high impact case reports 2023-01, Vol.11, p.23247096231217822-23247096231217822
Main Authors: Bathobakae, Lefika, Ozgur, Sacide S., Jariwala, Mohita, Kesrani, Jaydev, Ajas, Shajla, Kumar, Mehandar, Akmal, Amer
Format: Article
Language:English
Subjects:
Abdomen
Appendiceal Neoplasms - complications
Appendiceal Neoplasms - pathology
Cancer
Cancer surgery
Case reports
Female
Humans
Middle Aged
Mucocele - complications
Mucocele - pathology
Peritoneal Neoplasms - diagnosis
Peritoneal Neoplasms - therapy
Pseudomyxoma Peritonei - diagnosis
Pseudomyxoma Peritonei - drug therapy
Pseudomyxoma Peritonei - etiology
Pseudomyxoma Peritonei - pathology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pseudomyxoma peritonei (PMP) is a rare clinical entity characterized by widespread mucinous implants in the peritoneal cavity. Commonly seen in females in their 50s, PMP typically originates from ruptured appendiceal mucoceles that find refuge in the peritoneal space. Rarely, PMP may originate from the ovary, stomach, colon, or pancreas. Pseudomyxoma peritonei of colorectal origin is more malignant and has a lower survival rate. We report a case of a 59-year-old Hispanic woman with PMP who presented to the emergency room with a 3-month history of progressive abdominal distention. Pseudomyxoma peritonei was confirmed by computed tomography (CT) scan of the abdomen and pelvis and histopathology, and the patient underwent partial cytoreductive surgery. Given her Eastern Cooperative Oncology Group (ECOG) performance status of 1 despite extensive carcinomatosis, our patient may benefit from hyperthermic intraperitoneal chemotherapy (HIPEC) in the future.
ISSN:2324-7096
2324-7096
DOI:10.1177/23247096231217822